Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francisco Beraldi-Magalhães has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intensive care unit admission among adults with tuberculosis: a systematic review of clinical characteristics

    by Marjorie Fairuzy Stolarz, Melissa Ferrari Gomes, Gabriel Pavinati, Matheus Cordeiro Marchiotti, Francisco Beraldi de Magalhães, Gabriela Tavares Magnabosco

    INTRODUCTION Considered a major public health problem, tuberculosis (TB) may progress to severe forms requiring intensive care. Admission to intensive care units (ICUs) reflects complex clinical conditions, frequently associated with respiratory failure, sepsis, and multiple organ dysfunction.() In this context, identifying predictors of disease severity is essential to optimize clinical management and to guide more […] INTRODUCTION Considered a major public health problem, tuberculosis (TB) may progress to severe forms requiring intensive care. Admission to intensive care units (ICUs) reflects complex clinical conditions, frequently associated with respiratory failure, sepsis, and multiple organ dysfunction.() In this context, identifying predictors of disease severity is essential to optimize clinical management and to guide more […]

  • Open Access

    Avaliação da Cascata de Cuidado dos pacientes com tuberculose no município de Colombo

    by Lorrani Lopes Duffeck, Polyana Barbosa Silva, Francisco Beraldi Magalhães

    Este estudo avaliou a cascata de cuidado da tuberculose no município de Colombo, Paraná, entre 2017 e 2023. Realizou-se uma pesquisa observacional, retrospectiva e quantitativa com base em dados do SINAN, analisando perfil epidemiológico, acesso a exames e desfechos dos pacientes. Foram notificados 266 casos, com predominância de homens brancos entre 30 e 50 anos. A baciloscopia foi o exame mais utilizado, apesar da recomendação do teste molecular rápido, que teve baixa adesão. A taxa de cura foi de 61,6%, inferior à meta da OMS, e houve perda de seguimento de 60,2% dos pacientes durante o tratamento, com destaque para falhas no preenchimento das fichas de notificação. A análise demonstrou fragilidades nos critérios de encerramento de casos, especialmente em pacientes com baciloscopia positiva ao final do tratamento. A cascata de cuidado revelou pontos críticos na adesão, diagnóstico e monitoramento, sendo fundamental para direcionar intervenções no controle da tuberculose.

  • Open Access

    Hierarchical analysis of unsuccessful tuberculosis treatment among people living with HIV in Brazil using nationwide surveillance data

    by Lucas Vinícius de Lima, Gabriel Pavinati, Francisco Beraldi‐Magalhães, Rubia Laine de Paula Andrade‐Gonçalves, Aline Aparecida Monroe, Marcela Demitto Furtado, Rosana Rosseto de Oliveira, Daniele Maria Pelissari, Kleydson Bonfim Andrade Alves, Gabriela Tavares Magnabosco

    Introduction: People with tuberculosis‐HIV coinfection face multiple barriers to effective treatment, including social vulnerability, stigma and limited access to healthcare. This study examined factors associated with loss to follow‐up and death among individuals with tuberculosis‐HIV in Brazil. Methods: We conducted a longitudinal study using a nationally linked database from surveillance systems. Poisson regression models with robust variance were applied to identify factors associated with unfavourable outcomes, guided by a theoretical‐conceptual hierarchical framework. Results: We analysed data from 54 516 individuals. The median time to loss to treatment follow‐up was 115 days, with a cumulative proportion of 29.56%. Among the most consistent predictors of loss to follow‐up were homelessness (relative risk, RR 1.18; 95% confidence interval, 95% CI 1.16–1.19), tuberculosis retreatment (RR 1.16; 95% CI 1.15–1.17) and drug use (RR 1.15; 95% CI 1.14–1.16), whereas antiretroviral therapy use (RR 0.95; 95% CI 0.95–0.96) showed a negative association. The median time to death during tuberculosis treatment was 27 days, with a cumulative proportion of 27.54%. Higher risk of death was observed among individuals with CD4 counts 3 (RR 1.09; 95% CI 1.08–1.10), those experiencing homelessness (RR 1.08; 95% CI 1.06–1.10) and those with rifampicin resistance (RR 1.11; 95% CI 1.07–1.15). Conclusion: Key social, clinical and programmatic factors were associated with loss to follow‐up and death during tuberculosis treatment among people with HIV. Addressing these vulnerabilities is essential to improving treatment outcomes and advancing progress towards the 2030 targets.

  • Open Access

    Estágio de eliminação da hanseníase em Alagoas, 2001-2022: estudo ecológico

    by Lucas Vinícius de Lima, Gabriel Pavinati, Rayssa Gysele Teixeira da Silva, Itanielly Gomes Queiroz, Gustavo Laine Araújo de Oliveira, Sandra Maria Barbosa Durães, Miguel Angel Aragón López, Kleydson Bonfim Andrade Alves, Francisco Beraldi-Magalhães, Gabriela Tavares Magnabosco

    Objetivo: Analisar o cenário epidemiológico e o estágio de eliminação da hanseníase nos municípios de Alagoas, no período de 2001 a 2022.

  • Open Access

    Leprosy elimination phase in Alagoas, 2001-2022: an ecological study

    by Lucas Vinícius de Lima, Gabriel Pavinati, Rayssa Gysele Teixeira da Silva, Itanielly Gomes Queiroz, Gustavo Laine Araújo de Oliveira, Sandra Maria Barbosa Durães, Miguel Angel Aragón López, Kleydson Bonfim Andrade Alves, Francisco Beraldi-Magalhães, Gabriela Tavares Magnabosco

    Objective: To analyze the epidemiological scenario and leprosy elimination phase in the municipalities of Alagoas state, Brazil, from 2001 to 2022. Methods: This is an ecological study using surveillance data from the Notifiable Health Conditions Information System; detection and prevalence rates of the disease, along with absolute and relative frequencies, were used; temporal trends were evaluated using joinpoint regression, spatial autocorrelation was assessed with Moran’s index, and municipalities were classified according to the Leprosy Elimination Monitoring Tool (LEMT) proposed by the World Health Organization. Results: Between 2010 and 2022, there was a significant annual decrease of -2.89% (95% confidence interval [95%CI] -5.65; -0.91) in the prevalence rate, -4.43% (95%CI -6.56; -2.20) in the detection rate in the general population and -6.03% (95%CI -10.00; -1.46) in the detection rate in the population under 15 years of age; significant high-high clusters (p-value <0.050) were observed in the municipalities of Jacaré dos Homens, Pão de Açúcar and Carneiros; according to the LEMT in 2022: 7 (6.8%) municipalities were in phase 1 - up to interruption of transmission, 41 (40.2%) in phase 2 - up to disease elimination, 27 (26.5%) in phase 3 - post-elimination surveillance and 27 (26.5%) in phase 4 - non-endemic status. Conclusion: The data pointed to trends of reduction in the leprosy burden in the state, although some municipalities continue to show high rates; the use of LEMT with secondary data should be approached cautiously, as the absence of reported cases does not imply disease elimination in scenarios of underreporting and underdiagnosis.


  • Open Access

    Is the Pharmacokinetics of First-Line Anti-TB Drugs a Cause of High Mortality Rates in TB Patients Admitted to the ICU? A Non-Compartmental Pharmacokinetic Analysis

    by Francisco Beraldi-Magalhaes, Suzanne L. Parker, Cristina Sanches, Leandro Sousa Garcia, Brenda Karoline Souza Carvalho, Amanda Araujo Costa, Mariana Millan Fachi, Marcus Vinicius de Liz, Alexandra Brito de Souza, Izabella Picinin Safe, et al.

    Background: Patients with tuberculosis (TB) may develop multi-organ failure and require admission to intensive care. In these cases, the mortality rates are as high as 78% and may be caused by suboptimal serum concentrations of first-line TB drugs. This study aims to compare the pharmacokinetics of oral rifampin, isoniazid, pyrazinamide and ethambutol patients in intensive care units (ICU) to outpatients and to evaluate drug serum concentrations as a potential cause of mortality. Methods: A prospective pharmacokinetic (PK) study was performed in Amazonas State, Brazil. The primary PK parameters of outpatients who achieved clinical and microbiological cure were used as a comparative target in a non-compartmental analysis. Results: Thirteen ICU and twenty outpatients were recruited. The clearance and volume of distribution were lower for rifampin, isoniazid, pyrazinamide and ethambutol. ICU thirty-day mortality was 77% versus a cure rate of 89% in outpatients. Conclusions: ICU patients had a lower clearance and volume of distribution for rifampin, isoniazid, pyrazinamide and ethambutol compared to the outpatient group. These may reflect changes to organ function, impeded absorption and distribution to the site of infection in ICU patients and have the potential to impact clinical outcomes.


  • Open Access

    RELAÇÃO DA HISTOLOGIA DO SISTEMA IMUNOLÓGICO COM A COVID-19 E O LÚPUS ERITEMATOSO SISTÊMICO

    by Irlena Wisniewska de Moura, Mariana Araujo Pereira, Francisco Beraldi de Magalhães, Helena Messias Gomes, Lívia Bittencourt Tahan, Livia Matos Badotti

    Introduction: The immune system is responsible for the body's cellular and humoral immunity. It can be activated by the presence of external antigens, such as viruses, or by the production of autoantibodies, causing autoimmune diseases, such as systemic lupus erythematosus. Objective: The objective of this work was to describe the histology and functioning of the immune system and to understand the possibility of exacerbation of COVID-19 symptoms in patients with systemic lupus erythematosus. Method: This work is a narrative review of technical books and articles published in SciELO and PubMed. Results: The innate and adaptive immune system contains cells that populate the lymphoid organs. The coronavirus is an external agent that stimulates the production of antibodies and cytokine-secreting cells, whereas patients with systemic lupus erythematosus have autoantibodies that can compromise their own antigens, leading to inflammation. Conclusion: In conclusion, lymphoid tissue cells trigger an immune response against the coronavirus, while patients with systemic lupus erythematosus have autoimmunity and, when contracting COVID, can develop the exacerbated form of this disease by hypomethylation or demethylation of DNA, which can increase the cytokine levels.

  • Systematic review with network meta-analysis on the treatments for latent tuberculosis infection in children and adolescents

    by Josiane M. Santos, Mariana M. Fachi, Francisco Beraldi-Magalhães, Beatriz Böger, Allan M. Junker, Eric L. Domingos, Priscila Imazu, Fernando Fernandez-Llimos, Fernanda S. Tonin, Roberto Pontarolo


  • Efficacy and safety of daily treatments for drug-susceptible pulmonary tuberculosis: a systematic review and network meta-analysis

    by Priscila Imazu, Josiane M Santos, Francisco Beraldi-Magalhães, Fernando Fernandez-Llimos, Fernanda S Tonin, Roberto Pontarolo

    Objectives: To evaluate and update the evidence on the comparative efficacy and safety of antimicrobial drugs regimens for treating pulmonary drug-susceptible tuberculosis (DS-TB). Methods: A systematic review was performed with searches in PubMed and Scopus (PROSPERO-CRD42019141463). We included randomised controlled trials comparing the effect of any antimicrobial regimen lasting at least 2 weeks. The outcomes of interest were culture conversion and incidence of adverse events. Bayesian network meta-analyses and surface under the cumulative ranking curve (SUCRA) analyses were performed. Results were reported as odds ratio with 95% credibility intervals. Key findings: Fifteen studies were included the meta-analysis (n = 7560 patients). No regimen was statistically more effective than the WHO standard approach (rifampicin, isoniazid, ethambutol, and pyrazinamide). The use of rifapentine 450 mg instead of rifampicin in the standard regimen demonstrated to be statistically safer than all other options for serious adverse events (e.g. hepatotoxicity, arthralgia) (OR ranging from 0.0 [Crl 0.00–0.04] to 0.0 [0.00–0.97]; SUCRA probabilities of 10%). Therapies containing rifapentine (Rp1500HEZ, Rp900HEZ) and moxifloxacin (RMEZ, RHMZ) are effective regarding culture conversion, but statistical uncertainty on their safety profile exists. Conclusion: The WHO standard regimen remains an overall effective and safe alternative for DS-TB. For intensive phase treatments, drugs combinations with rifapentine and moxifloxacin seem to reduce treatment duration while maintaining efficacy.


  • Open Access

    Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation

    by Cristina Sanches, Geisa C. S. Alves, Andras Farkas, Samuel Dutra da Silva, Whocely Victor de Castro, Farah Maria Drummond Chequer, Francisco Beraldi-Magalhães, Igor Rafael dos Santos Magalhães, André de Oliveira Baldoni, Mark D. Chatfield, et al.

    Objectives: This study aimed to develop a piperacillin population PK model for critically ill Brazil-ian patients and describe interethnic variation using an external validation. Methods: Plasma samples were obtained from 24 ICU patients during the fifth day of piperacillin treatment and assayed by HPLC-UV. Population pharmacokinetic modelling was conducted using Pmetrics. Empiric dose of 4 g IV 6- and 8-hourly were simulated for 50 and 100% fT > MIC and the probabil-ity of target attainment (PTA) and the fractional target attainment (FTA) determined. Results: A two-compartment model was designed to describe the pharmacokinetics of critically ill Brazillian patients. Clearance and volume of distribution were (mean ± SD) 3.33 ± 1.24 L h−1 and 10.69 ± 4.50 L, respectively. Creatinine clearance was positively correlated with piperacillin clearance and a high creatinine clearance was associated with lower values of PTA and FTA. An external vali-dation was performed using data from two different ethnic ICU populations (n = 30), resulting in acceptable bias and precision. Conclusion: The primary pharmacokinetic parameters obtained from critically ill Brazilian patients were similar to those observed in studies performed in critically ill patients of other ethnicities. Based on our results, the use of dose adjustment based on creati-nine clearance is required in Brazilian patients.